 Pyrazoles
"Pyrazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
| Descriptor ID |
D011720
|
| MeSH Number(s) |
D03.383.129.539
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrazoles".
Below are MeSH descriptors whose meaning is more specific than "Pyrazoles".
This graph shows the total number of publications written about "Pyrazoles" by people in this website by year, and whether "Pyrazoles" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 | | 1999 | 0 | 1 | 1 | | 2001 | 1 | 0 | 1 | | 2002 | 0 | 1 | 1 | | 2003 | 0 | 1 | 1 | | 2004 | 4 | 0 | 4 | | 2005 | 1 | 1 | 2 | | 2006 | 4 | 2 | 6 | | 2007 | 1 | 1 | 2 | | 2008 | 5 | 4 | 9 | | 2009 | 3 | 3 | 6 | | 2010 | 9 | 2 | 11 | | 2011 | 4 | 5 | 9 | | 2012 | 14 | 8 | 22 | | 2013 | 13 | 10 | 23 | | 2014 | 5 | 4 | 9 | | 2015 | 12 | 4 | 16 | | 2016 | 5 | 12 | 17 | | 2017 | 5 | 8 | 13 | | 2018 | 8 | 5 | 13 | | 2019 | 7 | 4 | 11 | | 2020 | 5 | 6 | 11 | | 2021 | 13 | 10 | 23 | | 2022 | 1 | 19 | 20 | | 2023 | 1 | 18 | 19 | | 2024 | 10 | 8 | 18 | | 2025 | 12 | 12 | 24 | | 2026 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Pyrazoles" by people in Profiles.
-
Waliany S, Cooper AJ, Liu SV, Gautschi O, Rotow JK, Smith KER, Weber UM, Lee DH, Loong HHF, Patel JD, Pennell NA, Nagasaka M, Patel SA, Tan DSW, Solomon BJ, Kim TM, Pall G, Riess JW, Sun L, Früh M, Uy NF, Gadgeel S, Feng J, Do A, Falcon C, Leighl NB, Baik CS, Lai GGY, Ou SI, Cheung KSY, Patil T, Mansfield AS, Weiler D, Yeap BY, Wirth LJ, Gainor JF, Drilon A, Lin JJ. Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium. Clin Cancer Res. 2026 Mar 16; 32(6):1157-1168.
-
Sagel SD, Poore TS, Wagner BD, Xie J, Heltshe SL, Cross M, Bratcher PE, Taylor-Cousar JL, Wilson A, McBennett K, Morgan SJ, Singh PK, Nichols DP, Kelly A, Solomon GM. Long-term reductions in inflammation in people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor. Ann Am Thorac Soc. 2026 Feb 01; 23(2):241-251.
-
Liu CM, Fischer JL, Overdevest JB, Zemke AC, Strand MJ, Gudis DA, Kimple AJ, Tervo JP, DiMango E, Goralski JL, Keating C, Senior B, Stapleton AL, Taylor-Cousar JL, Beswick DM. Psychometric validity of the 22-item sinonasal outcome test in cystic fibrosis. J Cyst Fibros. 2026 Mar; 25(2):353-358.
-
Lyons ER, Vigers T, Simoni M, Lynn C, Muther E. Body Image Perceptions and Elexacaftor/Tezacaftor/Ivacaftor (ETI) Use in Adolescents and Young Adults Living With Cystic Fibrosis. Pediatr Pulmonol. 2025 Dec; 60(12):e71418.
-
Ye W, Magee JC, Huang S, Leung DH, Bozic M, Stoll J, C Ling S, Paranjape SM, Karnsakul W, Jay Freeman A, Schwarzenberg SJ, Palermo J, Alonso E, Green N, Masand P, Karmazyn B, Harned R, Navarro OM, Siegel MJ, Towbin A, Alazraki A, Otto RK, Nicholas JL, Narkewicz MR. Impact of elexacaftor/tezacaftor/ivacaftor on biomarkers of cystic fibrosis hepatobiliary involvement in the PUSH study. J Pediatr Gastroenterol Nutr. 2026 Feb; 82(2):350-357.
-
Shimano KA, Grimes AB, Kaicker S, Shah SJ, Gunn E, Bhat RV, Kochhar M, Rothman JA, Rose MJ, Briones M, Nakano TA, Lebensburger JD, Lambert MP, Fritch Lilla SA, Jesudas R, Lee-Miller CA, Thompson AA, Rifkin-Zenenberg S, Majumdar S, Crary SE, Hege K, Ford JB, Bies JJ, Fort J, Wynn TT, Hsieh L, Ruiz ME, Dinu B, Wong JMW, Kao PC, Kim TO, Arnold SD, Bennett CM, Despotovic JM, Klaassen RJ, Neufeld EJ, Neunert CE, London WB, Grace RF. Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment: The PINES Randomized Clinical Trial. JAMA. 2025 11 25; 334(20):1816-1826.
-
Waliany S, Roy SG, Pecci F, Weber UM, Sun F, Arter Z, Lomibao M, Alessi JV, Nishino M, Luo F, Repetto M, Falcon C, Do A, Peterson J, Liang J, Liu A, Nagasaka M, Ricciuti B, Drilon A, Ou SI, Neal JW, Patil T, Awad M, Yeap BY, Digumarthy SR, Lin JJ. Efficacy and Safety of Continuing Next-Generation ALK TKIs With Chemotherapy for Advanced ALK-Positive NSCLC: A Multicenter Retrospective Study. J Natl Compr Canc Netw. 2025 Nov 19; 23(12):522-530.
-
Knoll RL, Brauny MM, Robert E, Cloos L, Waser L, Hilbert K, Ulmer N, Hillen B, Birkner T, Bartolomaeus TUP, Nitsche O, Jarquín-Díaz VH, Lynch S, Gehring S, Maier L, Poplawska K, Forslund-Startceva SK. CFTR modulator therapy drives microbiome restructuring through improved host physiology in cystic fibrosis: the IMMProveCF phase IV trial. Nat Commun. 2025 Nov 18; 16(1):10111.
-
Vladar EK, Gillen AE, Yadav S, Murphree MR, Baraghoshi D, Harris JK, Pruesse E, Niemiec SS, Wilson AW, Hisert KB, Humphries SM, Strand M, Lynch DA, Seibold MA, Beswick DM, Taylor-Cousar JL. Transcriptomic and functional responses of the cystic fibrosis airway epithelium to CFTR modulator therapy. JCI Insight. 2025 Nov 10; 10(21).
-
Weitz JI, Kithcart AP, O'Brien MP, Levy O, Marin E, Onisko M, Mohammadi KA, Li D, Meagher KA, Chang HH, Olenchock BA, Gutstein DE, Segers A, Roberts RS, Bonaca MP, Raskob GE. Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials. Lancet. 2025 Nov 29; 406(10519):2551-2563.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|